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data are unavailable or insufﬁ cient, indirect comparison is increasingly used across 
therapy areas, reﬂ ected by recent NICE guidance. To maximise quality of submissions, 
analyses must use validated methodology, manage heterogeneity appropriately and
clearly justify decisions and usage of methods and comparators. Rationale for use of 
indirect comparisons is also required.
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OBJECTIVES: To explore key decision-makers’ agreement on desirable scenarios to
effectively implement health technologies in the public sector in the future. From 2006 
onwards, the Spanish government has undertaken several initiatives to establish a 
reliable mechanism for implementing technologies in the National Health System 
(NHS). METHODS: A naturalistic, qualitative, two phases study was conducted. The 
current situation of implementing health technologies’ in Spain was explored on an 
earlier study. Based on the present circumstances, both phases of this study sought to 
explore and determine the level of agreement amongst key decision- makers on suitable 
strategies to improve the existing conditions. Phase One: semi-structured interviews
explored their views on desirable scenarios to more effectively implement health
technologies in the public sector. Phase Two: the Delphi method determined the level
of agreement amongst participants on key messages consistently endorsed during the
interviews. Two rounds of questionnaires were required to consolidate consensus level.
RESULTS: A total of 35 interviews were conducted, including managers, researchers 
and evaluators across country. Several categories of information emerged and were 
assessed in the Delphi process amongst 26 participants. Most responses (q75%) agreed
on: 1) decision making: based on a demonstrated incremental cost-beneﬁ t ratio; 2) 
desirable attributes: efﬁ ciency and cost-beneﬁ t, safety and eﬁ cacy; 3) uniﬁ ed processes 
countrywide; 4) information: open and consistent management across, and within,
levels of decision, with the health technology evaluation agencies (HTEA), and the 
industry; 5) education: continued training of decision- makers; 6) evaluation model: 
organized HTEA, coordinating efforts, following up transparent, participative and
methodologically robust processes agreed across Europe; 7) ﬁ nancing mechanisms: 
more ﬂ exible, collaborative formulas to avoid blocking the implementation of cost-
beneﬁ cial technologies; and 8) the industry’s role: expert, legitimate provider, “trainer 
of trainees” CONCLUSIONS: These ﬁ ndings should serve the Spanish Health Author-
ities to effectively improve the implementation of health technologies in the NHS.
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OBJECTIVES: Reasons provided by the health technology appraisal (HTA) agencies 
for the guidance issued vary across the board. Following interest from a previous 
ISPOR presentation, we sought to further investigate the reasons for recommenda-
tion/rejection between NICE, SMC, CADTH, and PBAC with a speciﬁ c focus on
disease-speciﬁ c reasons. METHODS: A previously developed database was updated 
with data from submissions appraised between 31 May and 31 December 2008 by 
NICE, SMC, CADTH, and PBAC, in England/Wales, Scotland, Canada, and Australia,
respectively. Submissions with opposing decision outcomes were included and were
categorised by disease based on the BNF (cardiovascular system, CNS, endocrine
system, gastro-intestinal system, infections, malignant diseases and immunosuppres-
sion, musculoskeletal and joint diseases, nutrition and blood, obstetrics, gynaecology, 
and urinary tract disorders, respiratory system, and skin). Reasons for acceptance/
rejection were analysed across the disease categories. RESULTS: In total, 83 submis-
sions were included for analysis. Across all HTAs, the most common rejection reasons 
for skin disease interventions included “not more effective than comparators” and 
“not cost-effective”; these reasons were demonstrated in 100% of the submissions for
interventions relating to skin disorders. The most common rejection reasons in malig-
nant diseases and immunosuppression included “not cost-effective” and “concerns
over the economic model” (100% for both). The majority of the reasons for rejection
were reported in 50% or less of the submissions per disease group. Of the recom-
mended interventions, those for the treatment of skin disease were all “more effective
than placebo and comparators” as well as having a lower cost. Interventions for 
infectious diseases and obstetrics, gynaecology, and urinary tract disorders demon-
strated a wide range of reasons for rejection. CONCLUSIONS: Sub-group analysis 
categorised by disease provides further insight into the primary reasons for rejection 
and recommendation across HTA bodies. Analysing trends within these submissions
highlights potential obstacles for new interventions within a speciﬁ c disease area.
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OBJECTIVES: Review of HTA recommendations issued by the Consultative Council 
of AHTAPol in Poland. METHODS: Fifty-nine drug recommendations, January 
2007–58/16/2008, from September 2007 until October 2008, available online, were 
analyzed. Appraisals were grouped into positive and negative recommendations. The 
clinical and non-clinical reasons for rejection of use were studied. The positive guid-
ances were divided into recommendations with major, minor and without restrictions. 
RESULTS: Thirty-two HTA reports received negative recommendations; 26 on the 
grounds of clinical evidence and 6 because of non-clinical issues. Among 26 recom-
mendations, insufﬁ cient clinical effectiveness data was the most frequently stated
reason (18 cases). In other eight guidances, the argument of poor efﬁ cacy or safety 
was raised. Among non-clinical aspects, unacceptable cost-effectiveness ratio was 
given four times. The unacceptable budget impact and risk of off-label use were men-
tioned each one only once. Twenty-seven HTA reports received positive recommenda-
tions, of which 18 for use with major restrictions, 7 with minor restrictions and 2 
without additional restrictions. Among those 18 recommendations, several restrictions
were imposed simultaneously. The most common was prescription restricted to speciﬁ c
subpopulations (15 cases), followed by the need for an improvement of cost-effective-
ness (6 cases), use as second line (5 cases), use if intolerant to other treatment (3 cases), 
reimbursement within speciﬁ c period (2 cases). Among recommendations with minor 
restrictions, lowering price was mentioned ﬁ ve times and use by specialist twice. The 
appraisal of cost-effectiveness analysis was included more frequently in positive rather 
than negative quidances; 63% vs. 57%. The study revealed that an ICER was above 
WHO threshold, accepted by AHTAPoL, in 65% of positive recommendations. An 
ICER was below threshold in 44% of negative recommendations. CONCLUSIONS:
The negative and positive HTA guidances with major restrictions prevailed in Poland. 
Clinical rather than pharmacoeconomic aspects were the most common reason for an 
appraisal recommendation.
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OBJECTIVES: Budget impact analyses (BIAs), along with cost-effectiveness analyses, 
are an essential part of a comprehensive economic assessment of a new health technol-
ogy and increasingly required by national regulatory agencies and managed care
organizations. This study describes the characteristics and growth of BIAs published
in the literature over the past 5–6 years. METHODS: An initial search was conducted
using PubMed, a service of the U.S. National Library of Medicine. Approximately 
800 citations were retrieved using key words of “budget impact” and “budget analy-
sis” and limits of “English Language” and “published within the last 6 years”. Addi-
tional articles were obtained through ancestral and related article searches. All relevant 
BIA articles were identiﬁ ed through an initial title review and secondary abstract
review and included in this study. RESULTS: We identiﬁ ed 32 BIAs published between 
2003 and 2008. The number of studies published each year were 1 (2003), 3 (2004),
5 (2005), 6 (2006), 7 (2007) and 10 (2008), showing a steady upward trend. The
publishing journals had impact factors ranging from 1.985 to 5.888. Just over half of 
published studies (18/32) assessed budget impact of a health technology in the United 
States, while the remaining studies were performed in European countries, Canada 
and Brazil. Although the majority of published BIAs (22/32) examined budget impact
of a speciﬁ c drug, several studies assessed budget impact of various procedures e.g.
surgical, endoscopic. Fourteen (44%) of the published BIAs were performed in
conjunction with a cost-effectiveness analysis. CONCLUSIONS: Despite increased 
demand for and recent growth in number of published BIAs, the absolute number of 
BIA studies published in peer-reviewed journals remains limited. Future studies should
examine whether the quality of published BIAs has improved over time and examine 
changes in practices following the recently published recommendations of the ISPOR
Task Force on good research practices for BIAs.
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OBJECTIVES: The outcomes of health technology assessment (HTA) appraisals con-
ducted by appraising bodies vary greatly and are inﬂ uenced by a range of factors. The 
aim of this research was to determine whether the sequence of agencies in which HTAs
are submitted has an impact on the guidance issued. METHODS: Data from submis-
sions to NICE, SMC and CADTH between 1 November 2005 and 31 December 2008
were included. Only interventions appraised by at least two agencies were of interest.
Extracted information included the name of the intervention, the guidance issued and
the date of guidance. In addition, a correlation between the sequence of submission 
and guidance issued was assessed. RESULTS: A total of 46 interventions were submit-
ted to at least two appraising bodies. In 76% of cases, the ﬁ rst body to conduct
appraisals was the SMC. In contrast, only 4% of the submissions were submitted to
